Sander F. Rodrigo , Jan van Ramshorst , Georgette E. Hoogslag , Helèn Boden , Matthijs A. Velders , Suzanne C. Cannegieter , Helene Roelofs , Imad Al Younis , Petra Dibbets-Schneider , Willem E. Fibbe , Jaap Jan Zwaginga , Jeroen J. Bax , Martin J. Schalij , Saskia L. Beeres , Douwe E. Atsma
28 August 2013
In experimental studies, mesenchymal stem cell (MSC) transplantation in acute myocardial infarction (AMI) models has been associated with enhanced neovascularization and myogenesis. Clinical data however, are scarce. Therefore, the present study evaluates the safety and feasibility of intramyocardial MSC injection in nine patients, shortly after AMI during short-term and 5-year follow-up. Periprocedural safety analysis demonstrated one transient ischemic attack. No other adverse events related to MSC treatment were observed during 5-year follow-up. Clinical events were compared to a nonrandomized control group comprising 45 matched controls. A 5-year event-free survival after MSC-treatment was comparable to controls (89 vs. 91 %, P = 0.87). Echocardiographic imaging for evaluation of left ventricular function demonstrated improvements up to 5 years after MSC treatment. These findings were not significantly different when compared to controls. The present safety and feasibility study suggest that intramyocardial injection of MSC in patients shortly after AMI is feasible and safe up to 5-year follow-up.